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Dann	Okoth	(Nairobi,	Kenya):	I’m a journalist from the same country as the current Nobel 
Peace Prize holder, environmentalist Wangari Maathai. This question is directed to Dr. 
rodemeyer. Perhaps I should get some information to take back to Wangari Maathai on 
environmental conservation. How can GM help us conserve our environment? Thank 
you very much.
Michael	Rodemeyer: You’ll hear more about that in the next few days from people who 
are working on some of those applications. But certainly, one of the arguments, for ex-
ample is in forestry. If we can develop ways to meet the needs of populations for timber 
and wood products from more intensively managed plantations, harnessing genetics to 
make those trees more appropriate for those uses, then we can begin to take some pres-
sure from the destruction of natural forests, which is clearly an issue in many countries 
in the developing world. So that’s certainly one part of the issue. Bt crops potentially 
reduce the use of insecticides and drought resistance has the potential to conserve scarce 
water resources. There is a number of possible environmental applications that could be 
of benefit in the developing world.
Roger	Beachy: I think you can’t avoid the obvious. By increasing food yields per acre you 
also reduce the pressure to require more land. I listened recently to the governor of one 
of the states in Madagascar where very fine centers of biodiversity are in operation, and 
he was lauding the efforts of agencies, including the US government and the United 
Nations, for working with his state for conservation, although it was a very small piece, 
about 380 hectares. He said, “You know the problem is that our farmers grow cassava that 
are severely diseased, causing continuous need for more and more land. Can you help us 
get disease-resistant cassava so we don’t have to do that?” It’s a continuing challenge in 
these economies—struggling to maintain this vast wealth of important biodiversity along 
with food production. While we are considering value-added traits, such as plant-made 
pharmaceuticals, there is the expectation that our food needs will be met. Not instead 
of, but on top of.
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Okoth: In Kenya, we don’t have regulations in place to govern the agricultural biotechnol-
ogy sector. It’s in parliament, but the legislators keep turning it around every other year. 
Hopefully soon they will be able to debate and decide what to do. In terms of biotech-
nology research we are very well established, but the regulation part of it is dragging us 
down. I hope very soon they will formulate laws to regulate this and this economy will 
be on the way.
Oyeley	Olukayode	(Lagos,	Nigeria):	I don’t know whether to classify this as a question 
or an observation. In Nigeria we have the problem of bush burning and I think we are 
losing species of potential economic importance. Are there ways through biotechnology 
application and and regulation to conserve species that are at risk of extinction through 
bush-burning?
Rodemeyer: Part of the response to that is similar to what we’ve said before. Most of the 
diversity exists in unmanaged and natural areas, and to the extent that you save that habitat 
by doing agriculture and forestry in other places, you help take the pressure off development 
of those areas. That’s one answer. But there is a broader question—and this is certainly 
not something that I’m an expert on—of trying to identify and save, for example, seeds 
and other resources, creating a biological diversity type of inventory. Certainly others have 
tried to ensure that there is a “savings bank,” so that those genetic resources are at least 
available. But there is larger debate. Are we trying to preserve these things in place or are 
we trying to simply preserve them as germplasm for future development?
Beachy: In African countries where we’ve had discussions vis-à-vis biosafety, there was 
confusion between the importance of having biodiversity solved before implementing 
biosafety regulations. The issues are very separable. You are talking about agriculture in 
one case and biodiversity in the other, and the issue is not biotechnology’s impact on 
biodiversity. The question is, “Is agriculture affecting biodiversity?” And sometimes in 
countries where a scientist is not placed at the head of the regulatory agency, then other 
influences, other externalities and philosophies, enter the regulatory process from the 
standpoint of the environment that are not based in science. Our concern is, as science 
is respected at high levels in all countries, so science should make an informed impact on 
policies. That’s the challenge that we see in Africa. There’s concern that biodiversity is so 
important—and it really is—but the issue is biodiversity and agriculture, not biodiversity 
and biotechnology. Although those are very separable they are too often confused, and 
that stops countries from making decisions with regard to biotechnology. We heard that 
over and over and over at the Montreal Cartagena Biosafety Protocol meetings. These are 
important issues, but separable, and need to be dealt with differently.
Milt	Zaitlin	(Cornell	University,	Ithaca,	NY): Dr. rodemeyer, I’m not quite as comfortable 
as you are with your assertion that food system fears won’t carry over to these PMPs. I mean, 
let’s face it, the objection to bioengineered food is not based on science and is not always 
based on risk. There are activist organizations that are very effective in combating…[audio 
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lost]…rice and Anheuser Busch is a good example of that.
Shelton: Michael, it would be good if you state what the example is. I’m not sure everyone 
in the audience knows about rice and Anheuser Busch.
Rodemeyer: A company called Ventria is developing a transgenic rice to produce a number 
of proteins, including lactoferrin. There was opposition in California from conventional 
rice growers and they made an agreement with the University of Missouri, to carry out 
some field trials there. There was opposition from environmental consumer groups and, 
interestingly, from food companies and other producers. It’s not that people are concerned 
about the safety of the protein that is developed from the pharmaceutical plant. The con-
cern is over how to protect the food supply. Until there is some additional guidance on 
what those standards are going to be, there will be a clash. Some in the food industry and 
others have called for a ban on the use of pharmaceuticals produced in any food crop, to 
preclude adventitious presence in the food chain. On the other hand, some say that these 
proteins are ubiquitous and it makes no difference whether they get into our cornflakes 
or not. But that decision hasn’t been made yet, and that is part of the problem.
Beachy: This is an issue of marketing not an issue of safety. riceland is a major buyer of 
rice in the delta—in the Mississippi region and throughout Arkansas and Missouri and 
other growing areas—and the question is who buys their rice? Well, if it’s Kellogg and 
Kellogg said that there might be accidental mixing, whether it’s safe or not is not the 
issue. It’s a marketing issue because somebody in another company can say, “We grow 
our rice elsewhere, therefore, ours is not mixed.” Whether the contamination is 0.00% 
or 0.%, it becomes marketing, not safety. We certainly don’t want to be glib and think 
that the future for value-added traits will be smooth. It won’t. We’ve heard for the last 0 
years, “Just bring us a consumer product and the consumers will approve GM crops.” I 
think that’s a red herring and meant to put us off, meant to make us all feel like we are 
on the right track. I’m cynical at this point, after 0 years of agbiotech and still not get-
ting new products out very often. You have to be ready for every eventuality. There are 
so many products in development that are in great states of readiness that aren’t coming 
to market. There is such great fear of bringing things into foods. I must say I was very 
pleased to hear Michael’s positive leaning because that is not what I expected. I’m hopeful, 
but I wouldn’t say I’m optimistic.
Neal	Stewart	(University	of	Tennessee,	Knoxville,	TN): I’ve often wanted to ask this question 
but I’ve always hesitated and especially now that we’ve had such heavy stuff —bush burn-
ing and people starving. Well anyway, this is it. We are always thinking about benefits of, 
potential benefits of biotechnology in products. What about just fun stuff? For example, 
flowers with novel fluorescent traits or bioluminescence or just new colors? There was a 
company that spun out of Carnegie Mellon a few years ago that had bioluminescent squirt 
guns. So I guess my question is, “Would consumers actually need benefits if something 
was fun?” A genetically modified golf ball that would fly a thousand yards?
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Rodemeyer:	Now you’re talking benefits!
Stewart: But that would not necessarily be very safe, especially if I was hitting it. Are 
there any scale effects of risks and benefits that we apply to food vs. nonfood and then 
just frivolous stuff that is fun?
Beachy: remember that regulatory agencies no longer capture on just outcome, they now 
capture based upon method of production. That’s the major challenge. We’re not regulating 
product, we’re regulating process. As long as that’s the overriding consideration, then a golf 
ball that is locatable with a radio beam because of genes or luminescence will be regulated 
by those agencies and the cost goes up as a consequence. So, I think it gets back to this 
issue of rationalization of regulation. There is a way to rationalize and so far we’ve been 
in a reactive mode listening so much to every potential doomsday scenario in response to 
every product that comes out that we keep imposing more regulations. And so a few years 
ago the cost for a new product was a million dollars, then it went to five, now its twenty 
so what will it be in 5 years unless you bring regulation under rationalization?
Stewart: Of course, unless it’s a zebra fish—then there’s no regulation, right?
Rodemeyer: right. But the glowfish is, in fact, partly the answer to your question. I am 
unaware of any protests or consumer or environmental or ethical issues with response to 
having a genetically modified aquarium fish.
Beachy: Yet they were banned from certain counties in California. 
Rodemeyer: Well, except for California; maybe that’s an outlier. But it’s an interesting 
story. From consumers, from the public, I’ve heard absolutely nothing and I have talked 
to the folks who make this thing and they say they’ve heard very little.
Beachy: In the case of green roses—that’s also been a nonoffender. The blue rose, I suspect, 
would be the same.
Rodemeyer: One of the reasons I distinguish between food products and nonfood 
products—I’m not aware of any efforts to boycott blue jeans that have been made 
from—
Beachy: Patagonia did it.
Rodemeyer: Well you’re right, Patagonia maybe. There’s no reason that you couldn’t launch 
exactly the same campaigns against fabric that you launch against food and this is one 
of the reasons that I argue that this may be different because it’s not food. So that makes 
me a little bit more cautiously optimistic about these applications.
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Henry	Miller	(Hoover	Institution,	Stanford,	CA): There’s an interesting historical example 
that melds agriculture and the last question—fun aspects of biotech—and that’s the 
old example of Pseudomonas	syringae, the old ice-minus organism, that was field tested 
to prevent frost damage. Now, for those of you who don’t recall, frost is promoted on 
plants by an ice-nucleation protein that is in Pseudomonas	syringae. And so scientists at 
the University of California devised a mutant that lacked the gene for the ice nucleation 
protein and found that, indeed, it did have some protective effect. Now, the regulatory 
aspect of this is interesting. EPA in its wisdom decided that frost is a pest and so this 
deletion mutant of Pseudomonas	syringae is a pesticide, and they regulated it as a pesticide. 
As a result, although it was shown to be effective in field trials, ultimately it was never 
commercialized because it would have to be registered as a pesticide. Now, what gets us 
to the last questioner is that the wild-type Pseudomonas	syringae, which is ice-plus, is used 
in snowmaking equipment at ski resorts. It’s sprayed into the air and there are skiers all 
around. And what’s interesting about it is that if somebody using recombinant DNA 
techniques made an overproducing mutant, that would be regulated by USDA and/or 
the EPA at the cost of tens of millions of dollars for registration. This is the kind of thing 
that roger is talking about—the need for rationalizing regulation. Currently, it makes no 
sense. It’s extremely destructive. It limits the number of experiments that can be done, 
it limits what gets into the pipeline, it limits what gets through the pipeline and it raises 
the cost ultimately for anything that does manage to get through.
Ralph	Hardy	(NABC,	Ithaca,	NY): You were talking about the regulatory process. We 
have a number of people from foreign countries here that do not yet have regulatory 
processes. What sort of guidance might you give them, and just as a lead off to that, I 
might suggest the Canadian system vs. the US system. The Canadian system regulates 
on the basis of novel traits. The US system regulates on the basis of process. In the US 
system we can use ionizing radiation—all sorts of things that can be produce massive 
changes in genomes—that require no regulation, but if its by a molecular process it does. 
In the Canadian system if it’s a novel trait, it doesn’t matter how you got there, it requires 
regulation. So, I’d be interested in your comments on that and as an add-on question, 
you’ve described one way of getting containment of genes, could you assess where the 
other processes, like the Daphne Preuss synthetic chromosome and chloroplast modifica-
tion, fit into accomplishing the same end point?
Rodemeyer: Well ralph, I think you’ve just thrown the entire agenda off if you want to open 
up what the regulatory system should look like. The initial point is that the administra-
tion, back in 98, made a decision that we were going to regulate biotechnology using 
existing laws, and I would argue that part of the problem is that by having to shoehorn 
the review under our existing laws, we don’t have an optimal system in place. Everyone 
was concerned that if Congress enacted a new system it would be worse than what the 
regulators could invent on their own. So, I’m not sure I have any great wisdom to share 
with you about our own system. There is no question that the regulatory system has done 
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pretty well with respect to the crops that are out there today. I don’t think there are any 
major environmental issues. There are certainly no health issues. The issue that we have 
tried to raise is: is the system ready for the new kinds of products that are coming along? 
And as I said, given the nature of novelty, every time you get a new issue, regulators are 
going to want to ask new questions. I’m not sure there’s a magic bullet. There have been 
arguments that we should have a system with minimal or no regulations. But—and 
I’m probably going to get a lot of disagreement on this—the reason that we have ac-
ceptance of biotechnology in this country is largely because people have confidence in 
the institutions that regulate it. That’s one of the differences between us and Europe. I 
think no regulation would be a mistake because the people wouldn’t have confidence in 
the technology. You have to have a rational system that’s based on science and on actual 
risk. There’s no magic bullet.
Beachy: I agree that we needed regulations early on. That was an important thing to 
implement. We have built a bigger system than we need and more onerous than neces-
sary because we haven’t learned from the last 0 years. I mean a Bt gene, the same one 
put in crop “X” and approved, going into a second crop, or even into another variety 
by a different transformation event, gets re-regulated as if it’s not known before. What’s 
the rationale for that after 0 years of safe use of the Bt gene? What’s the rationale for 
limiting some of the use of the virus-resistance technology or some of the anti-fungal 
technology? The Canadian system regulates the protein product that gives a trait. China 
seems to have done it in a way that is rational and one that meets their needs. They are 
looking for ways to reduce the use of agriculture chemicals. So I think China has moved 
ahead in the regulatory process in a different way. I think Kenya and Nigeria have an 
opportunity to do it in a different way, learning from what we’ve done in the last 0 
years and what China is moving to. And rather than reinventing the wheel, you start 
with a knowledge-base after 0 years. And that’s what we don’t find in countries where 
the regulation is not in place. Most want to start over from scratch, as if we have never 
had regulation. That doesn’t make any sense. We don’t do that when we regulate drugs. 
Having approved aspirin or tylenol® in this country, they’re acceptable in Kenya because 
there is a long history of safety.
With regard to how else to control trait flow, this issue of gene-switching versus the 
artificial chromosomes are apples and oranges and the reason why Daphne Preuss pro-
motes the use of the artificial chromosome is to reduce the likelihood of insertion of the 
gene at a place on the chromosome where there might be a negative impact. That might 
be useful in some cases or to move full genes in. So there may be some advantages, but 
I think they are apples and oranges. They are not the same. There are other ways to get 
to trait-control. There might be suicide genes where with x numbers of generations you 
trigger the gene to come back out again. Or you may make expression dependent upon 
hybridization and if that hybrid outcrosses to something else it won’t function. There 
are lots of ways to do it. I think the one that’s the most effective will be one that you can 
control ultimately with a small molecule.
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Robert	Wager	(Malaspina	University,	Naimano,	BC): It seems to me that marketing of fear 
has been driving policies, to a greater or lesser extent in North America, but certainly to 
a great extent in international policies. The MOP  talks seemed almost totally driven by 
fear as opposed to science and I’m curious what your feeling is about the MOP  talks 
on the Cartagena Protocol.
Beachy: I was there for only  hours, which was a long enough time for me to be there. 
I was there with the Public research and regulation Foundation. This is a move that 
started in Holland and England to try to engage public-sector scientists from all around 
the world including in Africa, Latin America, Asia, South Asia, Southeast Asia, in the 
discussion of the impact that the Cartagena Biosafety Protocol has on public researchers 
like us. What are the impacts and how do they stop innovation? How are they preventing 
us from doing our jobs? As ralph indicated earlier, more than 70% of the biotechnology 
that is known about in the United States is done by his member organizations. If you 
look in developing countries, far more biotech is done in the public sector at KArI for 
example, or at universities in Nairobi and Abuja and other places around West, East and 
South Africa. That’s where it’s done. Yet lack of understanding of what biosafety is has 
prevented public-sector scientists from doing their jobs and delivering improved vegetables 
and grains for their populations. So, for the first time, public-sector scientists were not 
afraid to speak out, at MOP . We had a preliminary meeting at the Danforth Center in 
March and that group and more were in Montreal to understand the process and make 
inputs when given the opportunity to do so, to correct some of the misunderstandings. 
The feeling that I had there—the accusation is—this is a big multi-national way to take 
charge of food production worldwide, and by George we’re not going to have that hap-
pen and we’re going to put in place regulations to prevent that, while doing so under the 
guise of preventing transfer of DNA between my country and your country. In the past 
there was an intention to use the process to listen to the antitechnologist and to block 
applications of relevant biotechnology around the world. I do agree that that was the 
goal at MOP . I think we’ve seen a slowdown towards that, and maybe a realization that 
the public sector has a lot to contribute here. Some of the delegates at the conference 
expressed surprise that university people are actually doing biotechnology! They didn’t 
know—so that was a learning. We should have been there the last time. The public sector 
should have been a lot more vocal over the last 0 years than it has. We bear some of the 
responsibility for how far the Cartagena Protocol has already gone because we’ve not been 
there often enough. We haven’t spoken out. We haven’t made our voices heard. We need 
to find better ways to get our message across or we’ll look a lot like Austria or Switzerland 
in the next few years. There is a possibility we’ll see ourselves slip back.
Shelton: Michael, in the title of your talk you used the words “speed bumps.” You didn’t 
use “wrong streets” or “crashes,” so I’m taking that as an indication of an optimistic future 
for some of these products. I’d like to thank both speakers. It was a great session.
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